Cargando…
PD-1/PD-L Axis in Neuroinflammation: New Insights
The approval of immune checkpoint inhibitors (ICIs) by the Food and Drug Administration (FDA) led to an improvement in the treatment of several types of cancer. The main targets of these drugs are cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein-1/programmed death-ligand 1...
Autores principales: | Manenti, Susanna, Orrico, Mario, Masciocchi, Stefano, Mandelli, Alessandra, Finardi, Annamaria, Furlan, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222696/ https://www.ncbi.nlm.nih.gov/pubmed/35756927 http://dx.doi.org/10.3389/fneur.2022.877936 |
Ejemplares similares
-
Mir106b-25 and Mir17-92 Are Crucially Involved in the Development of Experimental Neuroinflammation
por: Finardi, Annamaria, et al.
Publicado: (2020) -
The impact of storage on extracellular vesicles: A systematic study
por: Gelibter, Stefano, et al.
Publicado: (2022) -
PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019) -
The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021) -
PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)